by Mercy's Bethany Pope
Key points:
- Mercy's Dr. Damon Broyles traveled to the United Kingdom with a BioSTL Global delegation that included health innovation leaders from the region.
- The goal of the visit was to encourage U.K. startups in digital healthcare innovation to enter the U.S. market in St. Louis.
- Mercy's successes with large health technology deployments across its footprint, its precision medicine programs and AI models were all received well.
- Under the agreement, U.K. startups and scaleups in digital healthcare innovation affiliated with Health Innovation Networks that want to enter the U.S. market will gain a soft landing in St. Louis.
ST. LOUIS - Mercy continues to bring innovative thought leadership to the communities it serves and beyond. Dr. Damon Broyles, Mercy vice president of clinical innovation, informatics and precision medicine, recently shared insights and helped attract new companies to St. Louis’ nationally recognized healthcare industry as part of BioSTL.
BioSTL Global, the international arm of BioSTL and the backbone of the region's bio-innovation ecosystem, reached an agreement with the innovation network commissioned by the United Kingdom’s National Health Service (NHS).
As a delegate member of BioSTL, Dr. Broyles participated in an overseas visit with representatives of the U.K.’s NHS who are seeking a destination for top U.K. healthcare innovation looking to scale in the U.S. St. Louis was presented as a headquarters largely due to the unique and compelling value proposition BioSTL and the St. Louis-Midwest ecosystem offers. The delegation included health innovation leaders from Mercy, Washington University in St. Louis and the healthcare AI industry.
“Mercy has maintained an ongoing relationship with BioSTL, participating in initiatives like the Global Innovation Summit to evaluate and adopt emerging health technologies,” Dr. Broyles said. “Mercy stands out for its ability to rapidly implement and scale innovations across a large, integrated system, making it a preferred partner for startups looking to deploy solutions quickly.”
Dr. Broyles shared Mercy’s success with large deployments at scale for new technologies like Aidoc, its precision medicine programs and AI models.
Under the agreement, U.K. startups and scaleups in digital healthcare innovation affiliated with Health Innovation Networks that want to enter the U.S. market will gain a soft landing in St. Louis. The area is home to a vibrant healthcare-innovation community and a $500 billion healthcare sector of providers, payers and pharmacy benefit managers – all potential partners for pilots, purchase deals, licensing or commercial scaling for new AI and digital health technology.
BioSTL Global has built a St. Louis-based comprehensive soft-landing program for global healthcare innovators looking to enter and scale the complex U.S. market. The program includes the Global Innovation Advisory, the Global Health Innovation Summit, the Center for Rural Health Innovation and the Healthcare AI Collaborative.
For more information, see BioSTL’s full news release.
About BioSTL Global
BioSTL Global is the international arm of BioSTL, tasked with elevating St. Louis' reputation around the world as a leading agricultural and healthcare ecosystem. BioSTL Global actively recruits high-potential bio-innovation startups to enter the U.S. market through St. Louis, and connects them with major regional healthcare systems, corporations, investors, and research institutions to help them succeed, and the local ecosystem grow.
About BioSTL
For 25 years, BioSTL has served as the backbone of St. Louis' bioscience innovation ecosystem, bringing together research institutions, startups, industry partners, investors, and global collaborators to accelerate impact. BioSTL advances innovation across agriculture and human health through global engagement initiatives, including the BioSTL Global Health Innovation Summit; through BioGenerator, its startup creation and investment arm; and through education-to-workforce programs that build a strong, inclusive talent pipeline. Together, these efforts position St. Louis as a globally connected center for bioscience-driven growth. Find out more at www.BioSTL.org.
About Health Innovation Networks
There are 15 health innovation networks, commissioned by NHS England and the Office for Life Sciences, to operate as the key innovation arm of the NHS. They are the health innovation adoption experts. They find, test, implement and scale innovation to improve health outcomes, increase productivity and support economic growth. They act as a bridge between health care providers, commissioners, academia and industry. By connecting these sectors, they help to build a pipeline of solutions for the NHS from research and product development to implementation and commercialization. Find out more at www.healthinnovationyh.org.uk/.
